1. Scrip
  2. >>New Products

Roche’s Subcutaneous Ocrevus Could Extend Access To Patients

 
• By Jessica Merrill

A subcutaneous formulation of Roche’s best-selling drug will offer an alternative to a lengthy intravenous infusion. Both versions will be priced the same.

Roche_Logo_Glass

A 10-minute subcutaneous formulation of Roche’s multiple sclerosis (MS) blockbuster Ocrevus (ocrelizumab) could be a convenient alternative to a two-hour intravenous infusion and could expand access for patients for whom it is difficult to reach an infusion center. The US Food and Drug Administration approved Ocrevus Zunovo (ocrelizumab and hyaluronidase) on 13 September. 

Key Takeaways

  • The US FDA approved a new subcutaneously administered version of Roche’s blockbuster multiple sclerosis drug Ocrevus.

The two formulations will be priced the same, though a subcutaneous administration can avoid some administration costs. Because the molecules...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from Scrip

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.

Chinese Biotech VC/PE Fundings Rise But Still Modest

 
• By Dexter Jie Yan

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.